Sarepta Therapeutics Announces At-the-Market Equity Offering Facility

Sarepta Therapeutics Announces At-the-Market Equity Offering Facility 
CAMBRIDGE, MA -- (Marketwired) -- 07/03/13 --  Sarepta Therapeutics,
Inc. (NASDAQ: SRPT), a developer of innovative RNA-based
therapeutics, entered into an At-the-Market (ATM) equity offering
sales agreement with Further Lane Securities, L.P., on July 3, 2013,
under which Sarepta may, from time to time, offer and sell shares of
its common stock having an aggregate value of up to $125 million
through Further Lane. Sarepta intends to use any proceeds from this
offering for general corporate purposes, including for manufacturing
scale up for eteplirsen, the planned confirmatory Phase III clinical
study of eteplirsen and early development activities related to
follow-on Duchenne muscular dystrophy drugs and other programs. 
Under the ATM equity offering sales agreement, sales of common stock,
if any, through Further Lane, will be made by means of ordinary
brokers' transactions, in privately negotiated transactions, or
otherwise, at market prices prevailing at the time of sales, prices
related to prevailing market prices or negotiated prices.  
The common stock will be offered under the company's existing
effective shelf registration statement (including a prospectus) filed
with the Securities and Exchange Commission. A prospectus supplement
related to the offering will be filed with the Securities and
Exchange Commission. Any offer, solicitation or sale will be made
only by means of the prospectus supplement and the accompanying
prospectus. Current and potential investors should read the
prospectus in the registration statement, and the prospectus
supplement relating to the at-the-market offering and other documents
the company has filed with the SEC for more complete information
about Sarepta and the at-the-market offering program. 
A copy of the prospectus supplement and accompanying prospectus
relating to these securities may be obtained by contacting Donjon
Group c/o Further Lane Securities, L.P., 555 Madison Avenue, 12th
Floor, New York, NY 10022, or by calling (646) 652-5862. 
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor may there be any sale of
Sarepta's common stock in any state or jurisdiction in which such an
offer, solicitation or s
ale would be unlawful prior to registration
or qualification under the securities law of any state or
About Sarepta Therapeutics
 Sarepta Therapeutics is focused on
developing first-in-class RNA-based therapeutics to improve and save
the lives of people affected by serious and life-threatening rare and
infectious diseases. Sarepta's diverse pipeline includes its lead
program eteplirsen, for Duchenne muscular dystrophy, as well as
potential treatments for some of the world's most lethal infectious
diseases. Sarepta aims to build a leading, independent biotech
company dedicated to translating its RNA-based science into
transformational therapeutics for patients who face significant unmet
medical needs. 
Forward-Looking Statements and Information
 This news release
contains forward-looking statements regarding the company's offering
from time to time of common stock and the associated use of proceeds,
and is based on the company's current expectations and judgment. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. Words
such as "believes," "anticipates," "plans," "expects," "will,"
"intends," "potential," "possible" and similar expressions are
intended to identify forward-looking statements. 
These forward-looking statements involve risks and uncertainties,
many of which are beyond Sarepta's control
. Known risk factors
include, among others: market conditions; clinical trials may not
demonstrate safety and efficacy of any of Sarepta's drug candidates
and/or Sarepta's antisense-based technology platform; development of
any of Sarepta's drug candidates may not result in funding from the
U.S. government in the anticipated amounts or on a timely basis, if
at all; scale-up of manufacturing may not be successful and any of
Sarepta's drug candidates may fail in development, may not receive
required regulatory approvals (including Subpart H accelerated
approval), or be delayed to a point where they do not become
commercially viable; Sarepta may need additional funds to conduct
research and development efforts. 
Any of the foregoing risks could materially and adversely affect
Sarepta's business, results of operations and the trading price of
Sarepta's common stock. For a detailed description of risks and
uncertainties Sarepta faces, you are encouraged to review the
official corporate documents filed with the Securities and Exchange
Commission. Sarepta does not undertake any obligation to publicly
update its forward-looking statements based on events or
circumstances after the date hereof. 
Sarepta Investor Contact:
Erin Cox
Sarepta Media Contact:
Jim Baker
Press spacebar to pause and continue. Press esc to stop.